ADSCC manufactures UAE’s first CAR-T cells to treat leukaemia
Abu Dhabi Stem Cells Center (ADSCC), a PureHealth subsidiary, has successfully manufactured the UAE’s first CAR-T cells to treat an 11-year-old boy with leukaemia. The procedure involved manufacturing the cellular product (CAR-T) at ADSCC’s Good Manufacturing Practices (GMP) laboratories.
ADSCC marks a milestone in medical innovation
Dr Yendry Ventura, CEO of ADSCC, said the success in creating CAR-T therapy in Abu Dhabi marks a momentous leap in their commitment to making a profound impact on a regional level. With the support of UAE’s leadership and the Department of Health – Abu Dhabi, they aim to revolutionise perceptions of cancer treatment by pushing the limits of what can be achieved through cell therapy.
CAR-T cell therapy now accessible in UAE
CAR-T cell therapy has long been a monopoly of foreign pharmaceutical companies and has been an approved treatment in the US since 2017. Due to its difficulty and sensitivity of manufacturing, its accessibility has been limited in the region. The launch of such an advanced technology in the country solidifies the UAE’s position as a global destination for medical advancements and research.
Murad’s father expresses gratitude for his son’s successful treatment
Murad’s father, Majid, expressed how delighted he was with the success of his son’s treatment, which is the first of its kind in the UAE. The team provided them with full information on the procedure, what to expect and the steps throughout the treatment.
